Huang S, Yang L, Huang M
Department of Kidney Internal Medicine, First Affiliated Hospital, Chengdu.
Hua Xi Yi Ke Da Xue Xue Bao. 1996 Sep;27(3):317-9.
A Before-after study based on self-comparison was conducted to assess the early efficacy of recombinant human erythropoietin (r-HuEPO) in 51 patients with uremic anemia who were subjected to dialyses. A significant elevation of levels of Hb and Hct was observed (P < 0.001, P < 0.005) after r-HuEPO therapy. And hemorheologic tests showed whole blood viscosity was obviously increased (P < 0.005), but no changes in plasmic viscosity and platelet adhesion rate were found (P > 0.05). No increase of blood pressure of the patients was noticed in the early period after treatment. The results revealed a satisfactory early efficacy with few sideeffects of the r-HuEPO treatment in uremic anemia.
开展了一项基于自身对照的前后研究，以评估重组人促红细胞生成素（r-HuEPO）对51例接受透析的尿毒症贫血患者的早期疗效。r-HuEPO治疗后，观察到血红蛋白（Hb）和血细胞比容（Hct）水平显著升高（P<0.001，P<0.005）。血液流变学检测显示全血黏度明显升高（P<0.005），但血浆黏度和血小板黏附率无变化（P>0.05）。治疗后早期未发现患者血压升高。结果显示，r-HuEPO治疗尿毒症贫血的早期疗效令人满意，且副作用较少。
